Cardiovascular risk profiles: A cross‐sectional study evaluating the generalizability of the glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials REWIND, LEADER and SUSTAIN‐6 to the real‐world type 2 diabetes population in the United Kingdom

AIMS: To determine the proportion of UK patients with type 2 diabetes (T2D) who meet the cardiovascular (CV) or combined CV/core eligibility criteria used for the CV outcome trials (CVOTs) of UK‐marketed glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) showing CV benefit (dulaglutide in REWIND,...

Descripción completa

Detalles Bibliográficos
Autores principales: Webb, Joanne, Mount, Julie, von Arx, Lill‐Brith, Rachman, Jonathan, Spanopoulos, Dionysis, Wood, Robert, Tritton, Theo, Massey, Olivia, Idris, Iskandar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299650/
https://www.ncbi.nlm.nih.gov/pubmed/34668637
http://dx.doi.org/10.1111/dom.14580

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299650/
https://www.ncbi.nlm.nih.gov/pubmed/34668637
http://dx.doi.org/10.1111/dom.14580

Ejemplares similares